Fiasp®, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults
Bagsværd, Denmark (ots/PRNewswire) - Canada first country to launch Fiasp® This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, Novo Nordisk announced that Fiasp®, a new, fast-acting mealtime insulin for the treatment of diabetes in ...